Work

ER and PI3K Independently Modulate Endocrine Resistance in ER-Positive Breast Cancer

Year: 2011

Type: article

Abstract: Endocrine therapy-resistant estrogen receptor-positive (ER(+)) breast cancer is the most common cause of breast cancer death. Miller and colleagues demonstrate that ligand-independent ER activity promotes the growth of breast cancer cells through CDK4/E2F. As an independent event, the phosphatidylinositol 3-kinase (PI3K) pathway is also upregulated in endocrine therapy-resistant cells. Promising preclinical evidence by several groups for the combination of an inhibitor of ligand-independent ER, fulvestrant, with PI3K inhibition, has led to the activation of trials evaluating this concept.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-11-0192

Authors: Brian A. Van Tine, Robert J. Crowder, Matthew J. Ellis

Institution: Washington University in St. Louis

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute